Cost-Effectiveness Of Pembrolizumab In Combination With Axitinib As First-Line Treatment For Advanced Renal Cell Carcinoma

Arielle G. Bensimon,Yichen Zhong,Umang Swami,Allison Briggs,Joshua Young,Yuan Feng,Yan Song,James Signorovitch,Oluwakayode Adejoro, Abhiroop Chakravarty,Mei Chen,Rodolfo F. Perini,Daniel M. Geynisman

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 1|浏览27

暂无评分

摘要

716Background: Pembrolizumab/axitinib significantly prolonged progression-free survival (PFS) and overall survival (OS) vs. sunitinib in a phase 3 trial KEYNOTE-426 among previously untreated patie...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要